Coda Biotherapeutics Closes $28 Million Financing Led By Pacira Biosciences

CODA Biotherapeutics, Inc. ("CODA"), a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform to treat neurological disorders with an initial focus on neuropathic pain and epilepsy, today announced it has closed on $28 million in financing led by Pacira BioSciences, Inc., together with the company's existing investors, MPM Capital and Versant Ventures, and a new venture debt round with Silicon Valley Bank (SVB). As part of the financing, David Stack, chairman and CEO of Pacira Biosciences, has joined CODA's board of directors.